Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02500251 · ClinicalTrials.gov registry record · Phase 1
Belimumab Impacting Transplant Eligibility
A Phase 1 study of Renal Transplant Rejection, sponsored by E. Steve Woodle.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 2
- Study locations
NCT02500251 is a Phase 1 study of Renal Transplant Rejection that has completed, run by E. Steve Woodle. The registered enrollment target is 11 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT02500251, a Phase 1 study of Renal Transplant Rejection, has completed, sponsored by E. Steve Woodle.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is a prospective, open label, phase I/II pilot study.
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Bortezomib
- DRUG belimumab
- DRUG Plasmapheresis
Study Locations (2)
Ohio
- The Christ Hospital - Cincinnati
- University of Cincinnati - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-06 |
| Est. Completion | 2018-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02500251
The ClinicalTrials.gov registry entry for NCT02500251 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is E. Steve Woodle, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Transplant Rejection appearing as the primary indexed condition, and to 4 interventions - of which Rituximab is the first listed.
NCT02500251 reports 2 study locations spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02500251 about?
NCT02500251 is a clinical study titled "Belimumab Impacting Transplant Eligibility". This study is a prospective, open label, phase I/II pilot study.
What is the current status of trial NCT02500251?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2015-06. Estimated completion is 2018-08.
What conditions does trial NCT02500251 study?
This clinical trial studies the following conditions: Renal Transplant Rejection.
What interventions are being tested in trial NCT02500251?
The interventions under investigation include: Rituximab (DRUG), Bortezomib (DRUG), belimumab (DRUG), Plasmapheresis (DRUG).
Who is sponsoring clinical trial NCT02500251?
This trial is sponsored by E. Steve Woodle, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02500251 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Transplant Rejection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.